News Minimalist logo

Oral spray vaccine MV140 prevents recurrent UTIs for years

Connected to India — April 8, 2024, 08:00 AM UTC

Summary: A study presented at the EAU Congress revealed that an oral spray-based vaccine, MV140, prevented recurrent UTIs for up to nine years in 54% of participants with no notable side effects. UTIs affect half of women and one in five men, with 20-30% developing recurrent infections. The vaccine, administered daily for three months, could be a game-changer in UTI prevention, potentially reducing the need for antibiotics.

Full article

Article metrics
Significance5.3
Scale7.5
Magnitude7.0
Potential8.5
Novelty8.0
Actionability6.0
Immediacy7.0
Positivity9.0
Credibility7.0

Timeline:

  1. [5.3]
    Oral spray vaccine prevents UTIs for up to 9 years (ABC News)
    37d
    Source
  2. [4.6]
    MV140 oral spray vaccine for UTI shows long-term efficacy (Onmanorama)
    40d
    Source
  3. [5.1]
    Oral spray vaccine prevents UTIs for up to 9 years (The Independent)
    41d
    Source
  4. [4.2]
    Uromune vaccine shows promise in preventing recurring UTIs long-term (The Mirror)
    41d
    Source
  5. [6.2]
    Oral spray vaccine MV140 prevents recurrent UTIs long-term (Cosmos)
    41d

    ScoresSource
  6. [6.6]
    Oral spray vaccine prevents recurring UTIs for up to 9 years (The Telegraph)
    41d

    ScoresSource